Skip to main content

Baupost Group

Superinvestor

Baupost Group LLC

SEC CIK
0001061768
Manager
Seth Klarman
Style
Value
Latest filing
Aug 13, 2026

FNCH holding history

Finch Therapeutics Group, Inc. in every 13F filed by Baupost Group, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

FNCH overviewAll 13F holders of FNCHFull Q2 2026 holdings

Shares (Q1 2024)
0
Sold out in Q1 2024
Value
$0
% of portfolio
0.0%
Quarters held
12
Since Q1 2021
Holdings of FNCH by Baupost Group, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q1 20240$00.0%−67,296−100.0%Sold outHolders
Q4 202367,296$243.0K<0.1%00.0%UnchangedHolders
Q3 202367,296$349.0K<0.1%00.0%UnchangedHolders
Q2 202367,296$574.0K<0.1%00.0%UnchangedConverted for a 1-for-30 splitHolders
Q1 20232,019,008$793.0K<0.1%+1,000,000+98.1%AddedHolders
Q4 20221,019,008$489.0K<0.1%−104,100−9.3%ReducedHolders
Q3 20221,123,108$1.88M<0.1%00.0%UnchangedHolders
Q2 20221,123,108$3.19M<0.1%00.0%UnchangedHolders
Q1 20221,123,108$5.65M0.1%−9,145−0.8%ReducedHolders
Q4 20211,132,253$11.3M0.1%−75,906−6.3%ReducedHolders
Q3 20211,208,159$15.7M0.1%00.0%UnchangedHolders
Q2 20211,208,159$16.7M0.1%00.0%UnchangedHolders
Q1 20211,208,159$18.9M0.2%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.